Trial Summary
What is the purpose of this trial?
This trial studies how well certain scans work in assessing the response of patients with breast cancer that has spread to the bones. The scans use a special substance to highlight active cancer areas on detailed body images, helping doctors see if the treatment is working. These scans have been used successfully for various stages and evaluations of breast cancer.
Research Team
Jennifer M. Specht
Principal Investigator
ECOG-ACRIN Cancer Research Group
Eligibility Criteria
This trial is for patients with breast cancer that has spread to the bones. Participants must have a life expectancy of at least 24 weeks, an ECOG performance status of <=2, and meet renal function guidelines. They should plan to receive specific systemic therapies like endocrine therapy or chemotherapy. Pregnant or breastfeeding women, those with certain other cancers or who've had extensive chemotherapy are excluded.Inclusion Criteria
My breast cancer has spread, is hormone receptor positive, and my HER2 status is known.
I am planning or currently receiving specific treatments for my metastatic breast cancer.
My kidney function is good enough for MRI and CT scans.
See 8 more
Exclusion Criteria
My cancer has not spread to my brain, membranes around the brain and spine, or filled my chest or abdomen cavities.
Patients currently participating in or have participated in a study of an investigational agent or using an investigational device within 3 weeks of study registration are not eligible
I have not had more than 3 chemotherapy treatments for my advanced breast cancer.
See 2 more
Treatment Details
Interventions
- Computed Tomography (Diagnostic Procedure)
- Fludeoxyglucose F-18 (Other)
- Positron Emission Tomography (Diagnostic Procedure)
Trial OverviewThe FEATURE study is testing how well FDG-PET/CT scans measure activity in bone-dominant metastatic breast cancer before and after treatment compared to standard imaging tests. This phase II trial aims to improve diagnostic accuracy for assessing responses in these patients.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Diagnostic (FDG-PET/CT)Experimental Treatment3 Interventions
Patients receive FDG IV and undergo PET/CT scan over 15-30 minutes at baseline (within 21 days before start of standard systemic treatment) and at 12 weeks after start of standard systemic treatment in the absence of unacceptable toxicity.
Find a Clinic Near You
Who Is Running the Clinical Trial?
ECOG-ACRIN Cancer Research Group
Lead Sponsor
Trials
122
Recruited
160,000+
National Cancer Institute (NCI)
Collaborator
Trials
14,080
Recruited
41,180,000+